Medical care costs associated with postmenopausal estrogen plus progestogen therapy

Value in Health

Volumn 7, Issue 5, 2004, Pages 544-553

  Ohsfeldt, Robert L ^a   Gavin, Norma I ^b   Thorp, John M ^c  

^a UNIVERSITY OF IOWA   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Costs; Hormone; Postmenopausal; Therapy

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST; CANADA; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL CARE; MEDICAL SERVICE; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT; PHYSICIAN; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; UTERUS;

EID: 6344221857     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.75006.x     Document Type: Article

References (29)

1. Leveille SG, LaCroix AZ, Newton KM, Keenan NL. Older women and hormone replacement therapy: factors influencing late life initiation. J Am Geriatr Soc 1997;45:1496-500.
2. Newton KM, LaCroix AZ, Leveille SG, et al. Women's beliefs and decisions about hormone replacement therapy. J Womens Health 1997;6:459-65.
3. Rosenberg L, Palmer JR, Rao RS, Adams-Campbell LL. Correlates of postmenopausal female hormone use among black women in the United States. Obstet Gynecol 1998;91:454-8.
4. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized clinical trial. J Am Med Assoc 2002;288:321-33.
5. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. J Am Med Assoc 2002;288:366-8.
6. Ettinger B, Selby JV, Citron JT, et al. Gynecologic complications of cyclic estrogen progestin therapy. Maturitas 1993;17:197-204.
7. Ettinger B, Li DK, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril 1998;69:865-9.
8. Saver BG, Taylor TR, Woods NF, Stevens NG. Physician policies on the use of preventive hormone therapy. Am J Prev Med 1997;13:358-65.
9. Thorp JM, Gavin NI, Ohsfeldt RL. Hormone replacement therapy in postmenopausal women: utilization of health care resources in new users. Am J Obstet Gynecol 2001;185:318-26.
10. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women's health initiative randomized trial. J Am Med Assoc 2003;290:1739-48.
11. US Preventive Services Task Force. Postmenopausal hormone prophylaxis. In: DiGuiseppi C, Atkins D, Woolf SH, eds., Guide to Clinical Preventive Services (2nd ed.). Washington, DC: Agency for Health Care Policy and Research, 1996.
12. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
13. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485-91.
14. Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996;88:643-9.
15. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of mammogrpahic screening. Lancet 2000;355:270-4.
16. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized Trial. J Am Med Assoc 2003;289:3243-53.
17. Ettinger B, Li D, Klein R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Maturitas 1996;3:185-9.
18. Gavin NI, Thorp JM, Ohsfeldt RL. Determinants of hormone replacement therapy duration among postmenopausal women with intact uteri. Menopause 2001;8:377-83.
19. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-13.
20. Blakely JA. The heart and estrogen/progestin replacement study revisited: hormone replacement therapy produced net harm, consistent with the observational data. Arch Intern Med 2000;160:2897-900.
21. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med 2000;160:2263-72.
22. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc 2000;283:1845-52.
23. Hoerger TJ, Downs KE, Lakshmanan MC, et al. Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal health risks. J Women Health G-B 1999;8:1077-89.
24. Strand LM, Downey W. Health databases in Saskatchewan. In: Strom BL, ed., Pharmocoepidemiology (2nd ed.). New York: Churchill Livingstone, 1994.
25. Organization for Economic Co-operation and Development (OECD). Purchasing Power Parities and Real Expenditures: 1996 Results. Paris, France: OECD, 1999.
26. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-95.
27. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998;17:247-81.
28. Chawla A, Kennedy S, Ohsfeldt R. Impact of postmenopausal hormone replacement therapy on resource utilization associated with adverse events. Value Health 1999;2:211.
29. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations rationale. Ann Intern Med 2002;137:834-9.